Prognostic and predictive factors in epithelial ovarian cancer;Facteurs pronostiques et prédictifs de réponse des tumeurs épithéliales malignes de l'ovaire

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages 425-437

  Boudou Rouquette, P ^a   Pautier, P ^a   Morice, P ^a   Lhomme C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Ovarian cancer; Predictive factor; Prognostic factor; Response to treatment

Indexed keywords

ALKYLATING AGENT; ANGIOGENIC FACTOR; ANTHRACYCLINE; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAXANE DERIVATIVE; TRASTUZUMAB; VALSPODAR; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CELL INFILTRATION; CYTOREDUCTIVE SURGERY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; PLOIDY; PROGNOSIS; REVIEW; TUMOR VOLUME;

FEMALE; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 66349086539     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0782     Document Type: Review

References (84)

1. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008 ; 56 : 159-175
2. Guérin S, Hill C, Doyon F. The frequency of cancer in France in 2006: mortality trends since 1950, incidence trend since 1980 and analysis of the discrepancied between this trends. Bull Cancer 2009 ; 96 : 51-57
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004 ; 351 : 2519-2529 (Pubitemid 39603165)
4. Laupacis A, Wells G, Richardson WS, Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine working Group. JAMA 1994 ; 272 : 234-237
5. Sobin LH, Wittekind C. TNM : classification des tumeurs malignes. Paris : Springer-Verlag, 2003.
6. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2003 ; 83 (Suppl 1) : 135-166 (Pubitemid 39658498)
7. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001 ; 357 : 176-182 (Pubitemid 32108089)
8. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. Br J Cancer 2007 ; 96 : 1817-1822 (Pubitemid 46912018)
9. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990 ; 75 : 263-273 (Pubitemid 20062245)
10. Lhommé C, Planchamp F, Joly F, Leblanc E, Albin N, Alliot C, et al. Surveillance Bulletin 2007. Guidelines for clinical practice: management of patients with malignant epithelial tumors of the ovary. First line medical treatment. Bull Cancer 2007 ; 94 : 1093-1106
11. Winter 3rd WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007 ; 25 : 3621-3627
12. International Collaborative Oncology Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002 ; 360 : 505-515 (Pubitemid 35232102)
13. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000 ; 19 : 7-15. (Pubitemid 30010638)
14. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001 ; 82 : 532-537 (Pubitemid 32826455)
15. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001 ; 81 : 398-403. (Pubitemid 32494653)
16. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DPJ, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004 ; 22 : 1040-1044 (Pubitemid 41095036)
17. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007 ; 60 : 355-360 (Pubitemid 46596552)
18. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005 ; 96 : 671-677 (Pubitemid 40255486)
19. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long-term survival in invasive ovarian cancer. Cancer 2000 ; 89 : 1783-1791
20. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 2005 ; 15 : 1014-1022
21. Khouja MH, Baekelandt M, Nesland JM, Holm R. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 2007 ; 26 : 418-425
22. Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope CG. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 1993 ; 169 : 40-52. (Pubitemid 23223926)
23. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003 ; 98 : 66-73. (Pubitemid 36741127)
24. Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 2004 ; 95 : 89-94. (Pubitemid 39286282)
25. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastella JP, et al. HER2 status in ovarian carcinomas: a multicentric GINECO study of 320 patients. PLoS ONE 2007 ; 2 : e1138.
26. Baekelandt M, Kristensen GB, Trope CG, Nesland JM, Holm R. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res 1999 ; 19 : 4469-4474 (Pubitemid 30042808)
27. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early-stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer 2004 ; 14 : 259-270 (Pubitemid 38533897)
28. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broet P, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2004 ; 91 : 470-475 (Pubitemid 39093565)
29. Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007 ; 106 : 221-232 (Pubitemid 46908745)
30. Crijns APG, Boezen HM, Schouten JP, Arts HJG, Hofstra RMW, Willemse PHB, et al. Prognostic factors in ovarian cancer: current evidence and future prospects. Eur J Cancer Suppl 2003 ; 1 : 127-145 (Pubitemid 39345490)
31. de Graeff P, Hall J, Crijns AP, de Bock GH, Paul J, Oien KA, et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer 2006 ; 95 : 627-633 (Pubitemid 44325903)
32. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004 ; 22 : 4700-4710 (Pubitemid 41185079)
33. Fehrmann RS, Li XY, van der Zee AG, de Jong S, Te Meerman GJ, de Vries EG, et al. Profiling studies in ovarian cancer: a review. Oncologist 2007 ; 12 : 960-966 (Pubitemid 47359138)
34. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, et al. Co-expression of Y box-binding protein-1 and Pglycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004 ; 93 : 287-291 (Pubitemid 38507591)
35. Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 2007 ; 98 : 1020-1026 (Pubitemid 46865386)
36. Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006 ; 100 : 330-337 (Pubitemid 43075265)
37. Young TW, Rosen DG, Mei FC, Li N, Liu J, Wang XF, et al. Upregulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Cancer Res 2007 ; 13 : 3848-3854 (Pubitemid 47037590)
38. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, et al. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 2004 ; 10 : 6559-6566 (Pubitemid 39346551)
39. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995 ; 64 : 280-285
40. Schneider J, Pollán M, Jiménez E, Marenbach K, Martínez N, Volm M, et al. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer 2000 ; 82 : 1662-1670 (Pubitemid 30229576)
41. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997 ; 3 : 999-1007. (Pubitemid 27252950)
42. Rodríguez-Rodríguez L, Sancho-Torres I, Mesonero C, Gibbon DG, Shih WJ, Zotalis G. The CD44 receptor is a molecular predictor of survival in ovarian cancer. Med Oncol 2003 ; 20 : 255-263 (Pubitemid 37193937)
43. Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003 ; 63 : 3066-3068 (Pubitemid 36735853)
44. Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993 ; 53 : 4550-4554 (Pubitemid 23304378)
45. Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, et al. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007 ; 13 : 4139-4145
46. Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 2003 ; 102 : 156-161
47. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+ / regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005 ; 102 : 18538-18543 (Pubitemid 43011261)
48. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007 ; 67 : 8901-8905 (Pubitemid 47437467)
49. Trimbos JB, Vergote I, Bolis G, Vermoken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer: adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003 ; 95 : 113-125 (Pubitemid 36193260)
50. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V, et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998 ; 9 : 1097-1101
51. Michel G, De Iaco P, Castaigne D, el-Hassan MJ, Lobreglio R, Lhomme C, et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1997 ; 18 : 9-15.
52. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003 ; 101 : 885-891 (Pubitemid 36561249)
53. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002 ; 20 : 1248-1259 (Pubitemid 34177431)
54. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003 ; 90 : 390-396 (Pubitemid 36952033)
55. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006 ; 103 : 559-564 (Pubitemid 44602167)
56. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, et al. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007 ; 106 : 69-74.
57. Morice P, et le groupe de travail SOR. Standards, Options: Recommandations 2007 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l'ovaire « traitement chirurgical ». Bull Cancer 2007 ; 94 : 995-1002.
58. Riedinger JM. Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study. Bull Cancer 2007 ; 94 : 287-295 (Pubitemid 46586781)
59. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005 ; 16 : 47-50.
60. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995 ; 332 : 629-634
61. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004 ; 351 : 2489-2497 (Pubitemid 39603156)
62. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhomme C, Pautier P, et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 2003 ; 14 : 74-77 (Pubitemid 36150262)
63. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006 ; 106 : 1933-1939 (Pubitemid 43673208)
64. Le T, Hopkins L, Faught W, Fung-Kee-Fung M. The lack of significance of CA125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 2007 ; 105 : 712-715 (Pubitemid 46734199)
65. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995 ; 11 : 1217-1228
66. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996 ; 56 : 689-693 (Pubitemid 26055453)
67. Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 1998 ; 78 : 375-381 (Pubitemid 28336426)
68. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995 ; 75 : 2147-2152
69. Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004 ; 92 : 31-39 (Pubitemid 38147368)
70. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003 ; 21 : 283-290 (Pubitemid 46606157)
71. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006 ; 118 : 1963-1971
72. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997 ; 65 : 130-137 (Pubitemid 27171563)
73. Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. Phase III study of Valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008 ; 26 : 2674-2682
74. Kaye SB. Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 2008 ; 26 : 2616-2618
75. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995 ; 87 : 1230-1237
76. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994 ; 94 : 703-708 (Pubitemid 24251002)
77. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007 ; 25 (33) : 5172-5179 (Pubitemid 350232247)
78. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003 ; 97 : 2187-2195 (Pubitemid 36444059)
79. Lacour RA, Westin SN, Daniels MS, Milam MR, Sun CC, Urbauer DL, et al. Survival in advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. J Clin Oncol 2007 ; 25 : 5514 (ASCO Part I).
80. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. J Clin Oncol 2008 ; 26 (1) : 20-25
81. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997 ; 8 : 963-968 (Pubitemid 27475726)
82. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 ; 9 : 389-393
83. Kaye S. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie ovarian Cancer-2.2 trial. Int J Gynecol Cancer 2005 ; 15 (suppl1) : 31-35 (Pubitemid 40696475)
84. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second line platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004 ; 22 : 3120-3125 (Pubitemid 41103725)